



Augmentation of Chimerism in Whole Organ Recipients by 
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WE HAD previously demonstrated the persistence of donor leukocytes in the peripheral blood and tissues 
of long-surviving kidney I and liver-~ recipients who had 
stable graft function many years after transplantation. I-I> 
Donor cell chimerism has since been noted bv other 
investigators in recipients of heart. 7 liver.~ kidn~y," and 
lunglO transplants. In an attempt to augment chimerism. 
and thereby facilitate graft function. we initiated a prospec-
tive trial to enhance this phenomenon by infusing 3 x 
101I/kg unaltered donor bone marrow cells perioperatively 
into an unmodified recipient of whole organ from the same 
donor. Additionally. 53 recipients of whole organ alone 
were monitored as controls. Reported herein are the first 2U 
of 64 study patients and 33 of 53 control patients who are 
more than 120 days posttransplantation. 
MATERIALS AND METHODS 
Patients 
Since December 1992. 64 patients have heen simultaneously trans-
planted with donor bone marrow and liver (n = 28). liver and islets 
(n = 1). kidney (n = 17), kidney and pancreas (n = ~). kidney and 
islets (n = 6), heart (n = 8), and lungs (11 = ~). Immediately after 
whole organ placement and without any recipient conditioning. 
unmodified donor bone marrow cells (3 x IO"/kg). harvested from 
the vertebral bodies. were infused through a central intravenous 
line. All patients were maintained on routine immunosuppression 
with Tacrolimus (FK 506: Prograf) and prednisone. All episodes of 
acute graft-versus-host (GVH) and host-versus-graft (HVG) reac-
tions were treated with transient alterations in immunosuppression 
that in some patients included a methylprednisolone recycle (1 g 
tapered to 20 mg/d over a o-day period). Rejection episodes that 
were not amenable to conventional therapy were treated addition-
ally with azathioprine and OKT3. In seven type I diabetic pallents. 
donor pancreatic islets (0.57-1.5 x IO"/recipient). isolated hv a 
modificallon of the automated method. I I were infused through the 
portal vein before bone marrow infusion hut after organ place-
ment. Additionally, 53 recipients of whole-organ allografts in whom 
consent to retrieve donor vertebral column was not available were 
monitored as contemporaneous controls. 
Determination of Chimerism 
Recipients' peripheral blood mononuclear cells (PBMC) were 
prepared weekly in the first month and monthly thereafter for the 
detection of donor cells by the follOWing techniques. 
Flow C:l'lometTV In all immunostaining procedures. fluorescein 
isothiocyanate (FITC)-conjugated monoclonal antibodies (MAbs: 
mouse-a-human) directed against the polymorphic epitopes of 
HLA class I or II were used to identify donor and recipient cd". 
The specificity and optimal dilution of each antihody was deter-
mined by staining donor spleen cells and recipieMs pre transplant 
peripheral blood mononuclear cells (PBMCs). To delineate lin-
210 
cages. phycoerythrin (PE)-conJugated mouse-a-human MAbs di-
rected against various leukocyte cell surface receptors were used. 
Single-color fluorescence-activated cell sorting (FACS) analysis 
was performed to identify and or sort donor cells. Fifty thousand 
events were acquired. and values of circulating donor cells less than 
0.5% were considered not quantifiable. 
Fluoresccm In Situ HvbridizatlOn PBMCs isolated from female 
recipients of male organs were used to prepare cytospins for 
subsequent staining with a biotinylated Y -chromosome-specific 
probe. Fluorescein isothiocyanate-conjugated avidin was used to 
visualize positive cells. 
Polvmerase Chain Reaction Oligonucleotides specific for either 
the sex-determining region of the Y -chromosome (male -+ female 
transplants) or for the appropriate mismatched MHC class II 
alleles were used to detect donor DNA in the reciplent's PBMCs by 
enhcr polymerase chain reaction (PCR) or competitive PCR 
(cPCR). The analvsis was conducted via a method described 
previously. I ~ . 
In Vitro Immune Monitoring 
Pre- and posttransplant monitoring of recipients' immune status 
was conducted via evaluating proliferative responses of their 
PBMCs to mitogens (concanavalin A and phytohemagglutinin). 
recall antigens (tetanus toxoid). and by mixed lymphocyte reactions 
(MLRs). 
RESULTS AND DISCUSSION 
No complication of bone marrow infusion was observed in 
any of the 64 patients who simultaneously received whole-
organ allografts. The first 17 of 20 bone marrow-aug-
mented patients with a follow-up of lRU to 612 days have 
excellent graft function. One heart and bone marrow recip-
ient died 267 days after transplant due to causes unrelated 
to marrow infusion. At autopsy. no evidence of rejection 
was found in the allograft: however. a relatively large 
thromboembolus was found in the right pulmonary artery, 
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Table 1, Organ Function of Recipients WIth or Without Donor Bone Marrow Augmentation 
T. Bilirubon Creallnlne C-Peptide Insulin No. 01 Pat_ts 
Type 01 TransplantatIOn n Postoperative day (mgldl) (mgldl) (pMlml) (Ulday) 01! Sterotds 
With bone marrow 
OlT 7 355:: 103' 0.5:: 0.3' 4 
OlT + islets 1 326 0.3 0.02 29 0 
CRT 9 395 :: 138' 1.7:: 0.9' 4 
CRT + islets 2 411. 422 2.2.1.9 0.44,0.11 32, 32 1 
Without bone marrow 
OlT 14 235:: 35' 0.8:: 0.4' 8 
CRT 9 250:: 33' 
HT 2 197. 197 
OlT. orthotopic liver transplantation; CRT. cadaveric renal transplantation. 
'Means := SD. 
which appeared to be infected. The exact cause of death is 
stili unknown. but it is of interest to note that a relative!) 
hlch potassium level (9.5 mEq/L) was found in the speci-
111,'n of vitreous humor that was recovered approximately 10 
l10urs after his death. 
Another patient. a recipient of kidney and bone marrow. 
was admitted on postoperative day 499 with pancreatitis 
and acute cellular rejection. His creatinine at the time of 
admission was 32 mg/dL and, given his worsening renal 
function, he was put on dialysis. Because of ongoing 
domestic problems. the patient had become noncompliant 
in the 6 weeks before admission. which included failure to 
lake immunosuppression regularly and resumption of ex-
cessive alcohol intake. The patient is currently on dialysis. It 
is unfortunate that this patient became noncompliant, 
because he had a rejection-free postopera.tive course and 
excellent graft function until his last admission. He also had 
evidence of circulating donor cells and exhibited stable 
donor-specific hyporeactivity in serial in vitro assays. The 
deliberate withdrawal of immunosuppression by this patient 
and its undesirable outcome have further reinforced our 
earlier contention that premature weaning or withdrawal of 
immunosuppression might have serious repercussions both 
for the patient and the graft. 
A third patient who received cadaveric bone marrow plus 
a kidney was admitted on postoperative day 456 with renal 
dysfunction (serum creatinine 3.4 mg/dL) and evidence of 
rejection on fine-needle aspiration biopsy. Since she had 
experienced previous rejection episodes, all of which re-
sponded to manipulations in her routine immunosuppres-
sion. she was started on a steroid recycle (1 g bolus tapered 
to 20 mg/d). However, despite this ongoing therapy, renal 
function deteriorated, which prompted the initiation of 
tr(!atment with antithymocyte globulin (ATGAM). Eleven 
(i;l\s after termination of ATGAM therapy. she presented 
With signs and symptoms of serum sickness for which she is 
being treated. She is currently on dialysis. 
Of the 53 control patients (recipients of whole organs 
alone), eight (liver n = 7, kidney n = 1) have died at varying 
times after transplantation. 




Although none of the bone marrow-augmented or con-
trol patients are off Tacrolimus. it is noteworthy that four of 
nine kidney recipients in the study group are off steroids. 
whereas in none of the recipients of kidney transplant alone 
has a steroid-free existence been achieved (Table 1). Liver 
function, on the contrary. was similar in both groups (Table 
1). After a relatively high circulating C-peptide activity. islet 
graft function was lost to rejection in two of three (liver plus 
islets, n = 1; kidney plus islets, n = 1) patients. Islet 
function in the third patient is high enough to warrant an 
insulin-free existence if and when immunosuppression. with 
its diabetogenic side effects, can be discontinued. Neverthe-
less. all three recipients of pancreatic islet cells are currently 
being maintained euglycemic by exogenous insulin (Table 
1). 
HVG and GVH reactions were expected and encoun-
tered. Mild to moderate acute cellular rejection episodes 
were witnessed in 11 of 19 bone marrow-augmented (58%) 
and in 16 of 25 control patients (64%) who survived for the 
duration of this study. Furthermore, histopathology of 
allograft rejection was similar in both groups, resolving 
completely with transient increase in routine immunosup-
pression. Asymptomatic GVH reaction of the skin was 
encountered in only two patients, both recipients of bone 
marrow and liver, whose resolution in one did not require 
any exogenous intervention, whereas a slight increase in 
routine steroid therapy resulted in complete regression in 
the other.13 
Evidence of circulating donor cells was present in 18 of 
18 study patients and in nine of 21 control patients in whom 
detection was possible by flow cytometry (Fig 1), PCR. or 
fluorescence in situ hybridization. Furthermore. evidence of 
evolving donor-specific hyporeactivity was found in seven 
of 17 (41 %) bone marrow-augmented patients and in four 
of 22 (18%) control patients, in whom in vitro testing by 
MLR was feasible. A more perceptible modulation of 
immune reactivity was seen in the liver and bone marrow 
recipients. in whom 62% showed donor-specific hyporeac-
tivity as compared with 21 % of the controls. 14 
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Fig 1. FACS profile of PBMC obtained from a recipient 314 days after bone marrow and kidney transplantation. (A) Isotype-matched 
irrelevant antibody used as control. (8) Monoclonal antibody specific for HLA class I (anti-S? IgG1; HBS9, ATCC, Rockville. MO) was 
used to identify circulating donor cells. PGE, percentage gated events. 
infusion of donor bone marrow at the time of whole-organ 
transplantation leads to augmentation of chimerism without 
undue risk to the patients. Given the augmentation of 
donor leukocyte chimerism and evidence in some recipients 
of evolving donor-specific hyporeactivity. it is tempting to 
speculate that these patients can realistically aspire to an 
eventual drug-free state. However. it must be emphasized 
that we do not anticipate weaning these patients off immu-
nosuppression in the near future. This cautious approach 
has emerged from our experience in withdrawing immuno-
suppression from long-surviving kidney and liver recipients, 
which has taught us that long-term follow-up is required to 
ascertain the feasibility of safely weaning patients off drugs. 
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